Thrivent Financial for Lutherans Grows Stock Position in RxSight, Inc. (NASDAQ:RXST)

Thrivent Financial for Lutherans grew its stake in RxSight, Inc. (NASDAQ:RXST - Free Report) by 53.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 352,626 shares of the company's stock after buying an additional 122,989 shares during the period. Thrivent Financial for Lutherans owned 0.88% of RxSight worth $12,124,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in RXST. Telemark Asset Management LLC raised its stake in shares of RxSight by 6.6% in the fourth quarter. Telemark Asset Management LLC now owns 321,000 shares of the company's stock worth $11,036,000 after purchasing an additional 20,000 shares during the last quarter. Swiss National Bank raised its position in RxSight by 2.6% during the 4th quarter. Swiss National Bank now owns 66,300 shares of the company's stock worth $2,279,000 after buying an additional 1,700 shares during the last quarter. AlphaQuest LLC lifted its stake in RxSight by 65.7% during the 4th quarter. AlphaQuest LLC now owns 5,086 shares of the company's stock valued at $175,000 after acquiring an additional 2,017 shares during the period. Aigen Investment Management LP purchased a new stake in shares of RxSight in the 4th quarter valued at $407,000. Finally, Victory Capital Management Inc. increased its stake in shares of RxSight by 4.7% in the fourth quarter. Victory Capital Management Inc. now owns 271,978 shares of the company's stock worth $9,351,000 after acquiring an additional 12,114 shares during the period. 78.78% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

RxSight Stock Performance

RxSight stock traded down $0.33 during trading on Wednesday, reaching $24.37. The company had a trading volume of 280,169 shares, compared to its average volume of 530,456. The firm's 50-day simple moving average is $29.40 and its 200 day simple moving average is $39.55. The firm has a market capitalization of $986.77 million, a PE ratio of -29.36 and a beta of 1.22. RxSight, Inc. has a 1-year low of $24.09 and a 1-year high of $66.54.

RxSight (NASDAQ:RXST - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.25). The company had revenue of $40.21 million for the quarter, compared to analysts' expectations of $40.23 million. RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. Analysts anticipate that RxSight, Inc. will post -0.7 EPS for the current year.

Insider Activity

In other RxSight news, Director Jesse Anderson Corley acquired 1,443 shares of the company's stock in a transaction that occurred on Wednesday, January 15th. The stock was bought at an average price of $31.18 per share, with a total value of $44,992.74. Following the purchase, the director now owns 1,443 shares in the company, valued at approximately $44,992.74. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Shweta Maniar sold 3,519 shares of the company's stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $30.87, for a total value of $108,631.53. Following the completion of the sale, the director now owns 7,383 shares of the company's stock, valued at $227,913.21. This trade represents a 32.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 9.36% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Bank of America decreased their target price on shares of RxSight from $60.00 to $36.00 and set a "buy" rating for the company in a research report on Friday, March 21st. Stifel Nicolaus lowered their target price on RxSight from $33.00 to $28.00 and set a "hold" rating on the stock in a research note on Wednesday, March 19th. JPMorgan Chase & Co. reduced their price target on RxSight from $62.00 to $40.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. UBS Group assumed coverage on RxSight in a research report on Friday, December 6th. They issued a "buy" rating and a $52.00 price objective on the stock. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $43.00 target price on shares of RxSight in a research note on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, RxSight currently has a consensus rating of "Moderate Buy" and a consensus price target of $49.33.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.